Back to top

Image: Bigstock

Grupo Supervielle Enters Overbought Territory: Is A Drop Coming?

Read MoreHide Full Article

Grupo Supervielle S.A. (SUPV - Free Report) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because SUPV is now in overbought territory with an RSI value of 71.40.

What is RSI?

RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.

Other Factors

Yet SUPV’s high RSI value isn’t the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions Grupo Supervielle’s stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of SUPV’s prospects for the near term.

Over the past one month, investors have witnessed 1 earnings estimate revision lower compared to none higher for the current year. The consensus estimate for SUPV’s has also been on a downward trend over the same time period too, as the estimates have fallen 14% over the last two months.

If this wasn’t enough, Grupo Supervielle also has a Zacks Rank #5 (Strong Sell)which puts it into unfortunate company among its peers. So, given all of these factors, investors may want to consider exiting this stock now before it falls back to Earth. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

 


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Grupo Supervielle S.A. (SUPV) - free report >>